TY  - JOUR
AU  - Denčić-Fekete, Marija
AU  - Terzić, Tatjana
AU  - Jaković, Ljubomir
AU  - Đurašinović, Vladislava
AU  - Karan-Đurašević, Teodora 
AU  - Radojković, Milica
AU  - Pavlović, Sonja
AU  - Bogdanović, Andrija
PY  - 2023
UR  - https://doiserbia.nb.rs/Article.aspx?ID=0042-84502200060D
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2191
AB  - Introduction. The presence of aneuploidy in patients diagnosed with chronic lymphocytic leukemia (CLL), except trisomy 12, is considered quite uncommon. Hyperdiploidy or near-tetraploidy (occurring in 1–3% of all CLL patients) usually confer a poor prognosis. Case report. We report a patient in a progressive phase of CLL with near–triploid karyotype. The prognosis of the disease was more precisely determined by applying the cytogenetic analysis of the karyotype and was complemented with molecular methods and pathohistological examination. The complex karyotype was accompanied by the TP53, C-MYC, and IGH gene disruptions, the most probable cause of rapid evolution into Richter’s syndrome. Conclusion. The use of comprehensive contemporary diagnostic techniques is highly recommended in patients who are in the progressive phase of CLL, primarily for the adequate choice of management strategy. The presented case confirms that aneuploidy in CLL patients indicates poor prognosis, which is in accordance with previous publications reporting on cases of CLL patients with aneuploidy.
AB  - Uvod. Prisustvo aneuploidije kod bolesnika sa dijagnozom hronične limfocitne leukemije (HLL), sa izuzetkom trizomije 12, smatra se retkom pojavom. Pojava hiperdiploidnog ili kariotipa blizu tetraploidnog broja hromozoma (koji se javlja kod 1–3% svih bolesnika sa HLL) smatra se lošim prognostičkim parametrom. Prikaz bolesnika. Prikazan je bolesnik u uznapredovaloj fazi HLL sa kariotipom blizu triploidnog broja hromozoma. Prognoza bolesti je preciznije određena citogenetičkom analizom kariotipa bolesnika, i dopunjena molekularnim metodama i patohistološkom analizom. Otkriveno je prisustvo kompleksnog kariotipa udruženog sa poremećajima u genima TP53, C-MYC i IGH, što je najverovatnije bio uzrok brze progresije u Rihterov sindrom. Zaključak. Primena savremenih dijagnostičkih metoda veoma je značajna kod bolesnika u uznapredovaloj fazi HLL, prvenstveno zbog adekvatnog terapijskog pristupa. Prikazani slučaj ukazuje da je prisustvo aneuploidije kod bolesnika sa HLL loš prognostički znak, što je u saglasnosti sa prethodno publikovanim prikazima bolesnika sa HLL i sa aneuploidijom u kariotipu.
T2  - Vojnosanitetski pregled
T1  - Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype
T1  - Brza progresija hronične limfocitne leukemije u Rihterov sindrom kod bolesnika sa kariotipom blizu triploidnog broja hromozom
EP  - 457
IS  - 5
SP  - 454
VL  - 80
DO  - 10.2298/VSP211111060D
ER  - 

@article{
author = "Denčić-Fekete, Marija and Terzić, Tatjana and Jaković, Ljubomir and Đurašinović, Vladislava and Karan-Đurašević, Teodora  and Radojković, Milica and Pavlović, Sonja and Bogdanović, Andrija",
year = "2023",
abstract = "Introduction. The presence of aneuploidy in patients diagnosed with chronic lymphocytic leukemia (CLL), except trisomy 12, is considered quite uncommon. Hyperdiploidy or near-tetraploidy (occurring in 1–3% of all CLL patients) usually confer a poor prognosis. Case report. We report a patient in a progressive phase of CLL with near–triploid karyotype. The prognosis of the disease was more precisely determined by applying the cytogenetic analysis of the karyotype and was complemented with molecular methods and pathohistological examination. The complex karyotype was accompanied by the TP53, C-MYC, and IGH gene disruptions, the most probable cause of rapid evolution into Richter’s syndrome. Conclusion. The use of comprehensive contemporary diagnostic techniques is highly recommended in patients who are in the progressive phase of CLL, primarily for the adequate choice of management strategy. The presented case confirms that aneuploidy in CLL patients indicates poor prognosis, which is in accordance with previous publications reporting on cases of CLL patients with aneuploidy., Uvod. Prisustvo aneuploidije kod bolesnika sa dijagnozom hronične limfocitne leukemije (HLL), sa izuzetkom trizomije 12, smatra se retkom pojavom. Pojava hiperdiploidnog ili kariotipa blizu tetraploidnog broja hromozoma (koji se javlja kod 1–3% svih bolesnika sa HLL) smatra se lošim prognostičkim parametrom. Prikaz bolesnika. Prikazan je bolesnik u uznapredovaloj fazi HLL sa kariotipom blizu triploidnog broja hromozoma. Prognoza bolesti je preciznije određena citogenetičkom analizom kariotipa bolesnika, i dopunjena molekularnim metodama i patohistološkom analizom. Otkriveno je prisustvo kompleksnog kariotipa udruženog sa poremećajima u genima TP53, C-MYC i IGH, što je najverovatnije bio uzrok brze progresije u Rihterov sindrom. Zaključak. Primena savremenih dijagnostičkih metoda veoma je značajna kod bolesnika u uznapredovaloj fazi HLL, prvenstveno zbog adekvatnog terapijskog pristupa. Prikazani slučaj ukazuje da je prisustvo aneuploidije kod bolesnika sa HLL loš prognostički znak, što je u saglasnosti sa prethodno publikovanim prikazima bolesnika sa HLL i sa aneuploidijom u kariotipu.",
journal = "Vojnosanitetski pregled",
title = "Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype, Brza progresija hronične limfocitne leukemije u Rihterov sindrom kod bolesnika sa kariotipom blizu triploidnog broja hromozom",
pages = "457-454",
number = "5",
volume = "80",
doi = "10.2298/VSP211111060D"
}

Denčić-Fekete, M., Terzić, T., Jaković, L., Đurašinović, V., Karan-Đurašević, T., Radojković, M., Pavlović, S.,& Bogdanović, A.. (2023). Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype. in Vojnosanitetski pregled, 80(5), 454-457.
https://doi.org/10.2298/VSP211111060D

Denčić-Fekete M, Terzić T, Jaković L, Đurašinović V, Karan-Đurašević T, Radojković M, Pavlović S, Bogdanović A. Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype. in Vojnosanitetski pregled. 2023;80(5):454-457.
doi:10.2298/VSP211111060D .

Denčić-Fekete, Marija, Terzić, Tatjana, Jaković, Ljubomir, Đurašinović, Vladislava, Karan-Đurašević, Teodora , Radojković, Milica, Pavlović, Sonja, Bogdanović, Andrija, "Rapid progression to Richter’s syndrome in a patient with chronic lymphocytic leukemia and near-triploid karyotype" in Vojnosanitetski pregled, 80, no. 5 (2023):454-457,
https://doi.org/10.2298/VSP211111060D . .

TY  - JOUR
AU  - Mihaljević, Biljana
AU  - Vuković, Vojin
AU  - Milić, Nataša
AU  - Karan-Đurašević, Teodora
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Marjanović, Irena
AU  - Denčić-Fekete, Marija
AU  - Đurašinović, Vladislava
AU  - Dragović-Ivančević, Tijana
AU  - Pavlović, Sonja
AU  - Antić, Darko
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1458
AB  - Uvod/Cilj Prognoza hronične limfocitne leukemije (HLL) značajno je unapređena u poslednje vreme. Među nekoliko prognostičkih modela čiji je cilj predviđanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostički indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita značaj pomenutih prognostičkih modela u pogledu predviđanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliničkog centra Srbije sa prosečno agresivnijim profilom bolesti u odnosu na opštu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa višim vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju značajno ranije u poređenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p  lt  0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostički značaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj značaj izgubio. CLL-IPI je bio jedini značajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). Zaključak CLL-IPI, PRS i naročito MDACC 2011 su dobri prediktori TTFT čak i u kohortama bolesnika sa agresivnijom bolešću, dok je za predikciju OS od ova tri prognostička modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostičke modele trebalo ispitati na bolesnicima sa HLL u različitim fazama bolesti, kakvi se sreću u realnoj kliničkoj praksi.
AB  - Introduction/Objective Prognostication of chronic lymphocytic leukemia (CLL) has been substantially improved in recent times. Among several prognostic models (PMs) focused on the prediction of time to first treatment (TTFT), progression-risk score (PRS), and MD Anderson Cancer Center score 2011 (MDACC 2011) are the most relevant, while CLL-International Prognostic Index (CLL-IPI), although originally developed to predict overall survival (OS), is also being used to estimate TTFT. The aim of this study was to investigate CLL-IPI, PRS, and MDACC 2011 prognostic values regarding TTFT and OS. Methods The analyzed cohort included 57 unselected Serbian CLL patients from a single institution, with the basic characteristics reflecting more aggressive disease than in the general de novo CLL population. The eligible patients were assigned investigated PMs, and TTFT and OS analyses were performed. Results Patients with higher risk scores according to CLL-IPI, PRS, and MDACC 2011 underwent treatment significantly earlier than patients with lower risk scores (p = 0.002, p = 0.019, and p  lt  0.001, respectively). In multivariate analysis, MDACC 2011 and CLL-IPI retained their significance regarding TTFT (p = 0.001 and p = 0.018, respectively), while PRS did not. CLL-IPI was the only significant predictor of OS both at the univariate (p = 0.005) and multivariate (p = 0.013) levels. Conclusion CLL-IPI, PRS, and particularly MDACC 2011 are able to predict TTFT even in cohorts with more advanced-disease patients, while for prediction of OS, CLL-IPI is the only applicable among the three PMs. These results imply that PMs should be investigated in more diverse CLL populations, as it is in real-life setting.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra
T1  - Comparative analysis of International Prognostic Index for chronic lymphocytic leukemia, progression-risk score, and MD Anderson Cancer Center 2011 score: A single center experience
EP  - 421
IS  - 7-8
SP  - 415
VL  - 149
DO  - 10.2298/SARH201005047M
ER  - 

@article{
author = "Mihaljević, Biljana and Vuković, Vojin and Milić, Nataša and Karan-Đurašević, Teodora and Tošić, Nataša and Kostić, Tatjana and Marjanović, Irena and Denčić-Fekete, Marija and Đurašinović, Vladislava and Dragović-Ivančević, Tijana and Pavlović, Sonja and Antić, Darko",
year = "2021",
abstract = "Uvod/Cilj Prognoza hronične limfocitne leukemije (HLL) značajno je unapređena u poslednje vreme. Među nekoliko prognostičkih modela čiji je cilj predviđanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostički indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita značaj pomenutih prognostičkih modela u pogledu predviđanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliničkog centra Srbije sa prosečno agresivnijim profilom bolesti u odnosu na opštu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa višim vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju značajno ranije u poređenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p  lt  0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostički značaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj značaj izgubio. CLL-IPI je bio jedini značajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). Zaključak CLL-IPI, PRS i naročito MDACC 2011 su dobri prediktori TTFT čak i u kohortama bolesnika sa agresivnijom bolešću, dok je za predikciju OS od ova tri prognostička modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostičke modele trebalo ispitati na bolesnicima sa HLL u različitim fazama bolesti, kakvi se sreću u realnoj kliničkoj praksi., Introduction/Objective Prognostication of chronic lymphocytic leukemia (CLL) has been substantially improved in recent times. Among several prognostic models (PMs) focused on the prediction of time to first treatment (TTFT), progression-risk score (PRS), and MD Anderson Cancer Center score 2011 (MDACC 2011) are the most relevant, while CLL-International Prognostic Index (CLL-IPI), although originally developed to predict overall survival (OS), is also being used to estimate TTFT. The aim of this study was to investigate CLL-IPI, PRS, and MDACC 2011 prognostic values regarding TTFT and OS. Methods The analyzed cohort included 57 unselected Serbian CLL patients from a single institution, with the basic characteristics reflecting more aggressive disease than in the general de novo CLL population. The eligible patients were assigned investigated PMs, and TTFT and OS analyses were performed. Results Patients with higher risk scores according to CLL-IPI, PRS, and MDACC 2011 underwent treatment significantly earlier than patients with lower risk scores (p = 0.002, p = 0.019, and p  lt  0.001, respectively). In multivariate analysis, MDACC 2011 and CLL-IPI retained their significance regarding TTFT (p = 0.001 and p = 0.018, respectively), while PRS did not. CLL-IPI was the only significant predictor of OS both at the univariate (p = 0.005) and multivariate (p = 0.013) levels. Conclusion CLL-IPI, PRS, and particularly MDACC 2011 are able to predict TTFT even in cohorts with more advanced-disease patients, while for prediction of OS, CLL-IPI is the only applicable among the three PMs. These results imply that PMs should be investigated in more diverse CLL populations, as it is in real-life setting.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra, Comparative analysis of International Prognostic Index for chronic lymphocytic leukemia, progression-risk score, and MD Anderson Cancer Center 2011 score: A single center experience",
pages = "421-415",
number = "7-8",
volume = "149",
doi = "10.2298/SARH201005047M"
}

Mihaljević, B., Vuković, V., Milić, N., Karan-Đurašević, T., Tošić, N., Kostić, T., Marjanović, I., Denčić-Fekete, M., Đurašinović, V., Dragović-Ivančević, T., Pavlović, S.,& Antić, D.. (2021). Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 149(7-8), 415-421.
https://doi.org/10.2298/SARH201005047M

Mihaljević B, Vuković V, Milić N, Karan-Đurašević T, Tošić N, Kostić T, Marjanović I, Denčić-Fekete M, Đurašinović V, Dragović-Ivančević T, Pavlović S, Antić D. Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra. in Srpski arhiv za celokupno lekarstvo. 2021;149(7-8):415-421.
doi:10.2298/SARH201005047M .

Mihaljević, Biljana, Vuković, Vojin, Milić, Nataša, Karan-Đurašević, Teodora, Tošić, Nataša, Kostić, Tatjana, Marjanović, Irena, Denčić-Fekete, Marija, Đurašinović, Vladislava, Dragović-Ivančević, Tijana, Pavlović, Sonja, Antić, Darko, "Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra" in Srpski arhiv za celokupno lekarstvo, 149, no. 7-8 (2021):415-421,
https://doi.org/10.2298/SARH201005047M . .

TY  - JOUR
AU  - Vuković, Vojin
AU  - Karan-Đurašević, Teodora
AU  - Antić, Darko
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Marjanović, Irena
AU  - Denčić-Fekete, Marija
AU  - Đurašinović, Vladislava
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1321
AB  - Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Forty-four CLL patients with functional TP53 gene at the time of FC initiation were enrolled in this study. CYP2B6 genotyping was performed by polymerase chain reaction and direct sequencing. SLC28A3 expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Significantly higher pretreatment levels of SLC28A3 mRNA were detected in patients who failed to respond to FC in comparison to patients who achieved complete and partial response (p = 0.01). SLC28A3 high-expressing cases were almost ten times more likely not to respond to FC than low-expressing cases (OR = 9.8; p = 0.046). However, association of SLC28A3 expression with progression-free survival (PFS) and overall survival (OS) was not observed. CYP2B6*6 allele, detected in 24 patients (54.6%), exerted no association with the attainment of response to FC, as well as with PFS and OS. The results of this study demonstrate that SLC28A3 expression is a significant predictor of FC efficacy in CLL patients with intact TP53. Elevated SLC28A3 mRNA levels are associated with inferior short-term response to FC, suggesting that, if validated on larger cohorts, SLC28A3 expression may become a biomarker useful for pretreatment stratification of patients.
PB  - Frontiers Media Sa, Lausanne
T2  - Pathology & Oncology Research
T1  - Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients
EP  - 752
IS  - 2
SP  - 743
VL  - 26
DO  - 10.1007/s12253-019-00613-4
ER  - 

@article{
author = "Vuković, Vojin and Karan-Đurašević, Teodora and Antić, Darko and Tošić, Nataša and Kostić, Tatjana and Marjanović, Irena and Denčić-Fekete, Marija and Đurašinović, Vladislava and Pavlović, Sonja and Mihaljević, Biljana",
year = "2020",
abstract = "Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Forty-four CLL patients with functional TP53 gene at the time of FC initiation were enrolled in this study. CYP2B6 genotyping was performed by polymerase chain reaction and direct sequencing. SLC28A3 expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Significantly higher pretreatment levels of SLC28A3 mRNA were detected in patients who failed to respond to FC in comparison to patients who achieved complete and partial response (p = 0.01). SLC28A3 high-expressing cases were almost ten times more likely not to respond to FC than low-expressing cases (OR = 9.8; p = 0.046). However, association of SLC28A3 expression with progression-free survival (PFS) and overall survival (OS) was not observed. CYP2B6*6 allele, detected in 24 patients (54.6%), exerted no association with the attainment of response to FC, as well as with PFS and OS. The results of this study demonstrate that SLC28A3 expression is a significant predictor of FC efficacy in CLL patients with intact TP53. Elevated SLC28A3 mRNA levels are associated with inferior short-term response to FC, suggesting that, if validated on larger cohorts, SLC28A3 expression may become a biomarker useful for pretreatment stratification of patients.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Pathology & Oncology Research",
title = "Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients",
pages = "752-743",
number = "2",
volume = "26",
doi = "10.1007/s12253-019-00613-4"
}

Vuković, V., Karan-Đurašević, T., Antić, D., Tošić, N., Kostić, T., Marjanović, I., Denčić-Fekete, M., Đurašinović, V., Pavlović, S.,& Mihaljević, B.. (2020). Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. in Pathology & Oncology Research
Frontiers Media Sa, Lausanne., 26(2), 743-752.
https://doi.org/10.1007/s12253-019-00613-4

Vuković V, Karan-Đurašević T, Antić D, Tošić N, Kostić T, Marjanović I, Denčić-Fekete M, Đurašinović V, Pavlović S, Mihaljević B. Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. in Pathology & Oncology Research. 2020;26(2):743-752.
doi:10.1007/s12253-019-00613-4 .

Vuković, Vojin, Karan-Đurašević, Teodora, Antić, Darko, Tošić, Nataša, Kostić, Tatjana, Marjanović, Irena, Denčić-Fekete, Marija, Đurašinović, Vladislava, Pavlović, Sonja, Mihaljević, Biljana, "Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients" in Pathology & Oncology Research, 26, no. 2 (2020):743-752,
https://doi.org/10.1007/s12253-019-00613-4 . .

TY  - CONF
AU  - Vuković, V.
AU  - Antić, Darko
AU  - Karan-Đurašević, Teodora
AU  - Milić, N.
AU  - Todorovic-Balint, M.
AU  - Bila, J.
AU  - Anđelić, Boško
AU  - Đurašinović, Vladislava
AU  - Sretenović, A.
AU  - Smiljanić, M.
AU  - Jelicić, J.
AU  - Denčić-Fekete, Marija
AU  - Perunicić-Jovanović, M.
AU  - Kraguljac-Kurtović, N.
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1075
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution
EP  - 719
SP  - 719
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1075
ER  - 

@conference{
author = "Vuković, V. and Antić, Darko and Karan-Đurašević, Teodora and Milić, N. and Todorovic-Balint, M. and Bila, J. and Anđelić, Boško and Đurašinović, Vladislava and Sretenović, A. and Smiljanić, M. and Jelicić, J. and Denčić-Fekete, Marija and Perunicić-Jovanović, M. and Kraguljac-Kurtović, N. and Pavlović, Sonja and Mihaljević, B.",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution",
pages = "719-719",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1075"
}

Vuković, V., Antić, D., Karan-Đurašević, T., Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, B., Đurašinović, V., Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, M., Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, S.,& Mihaljević, B.. (2017). Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 719-719.
https://hdl.handle.net/21.15107/rcub_imagine_1075

Vuković V, Antić D, Karan-Đurašević T, Milić N, Todorovic-Balint M, Bila J, Anđelić B, Đurašinović V, Sretenović A, Smiljanić M, Jelicić J, Denčić-Fekete M, Perunicić-Jovanović M, Kraguljac-Kurtović N, Pavlović S, Mihaljević B. Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution. in Haematologica-The Hematology Journal. 2017;102:719-719.
https://hdl.handle.net/21.15107/rcub_imagine_1075 .

Vuković, V., Antić, Darko, Karan-Đurašević, Teodora, Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, Boško, Đurašinović, Vladislava, Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, Marija, Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, Sonja, Mihaljević, B., "Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution" in Haematologica-The Hematology Journal, 102 (2017):719-719,
https://hdl.handle.net/21.15107/rcub_imagine_1075 .

TY  - CONF
AU  - Vuković, V.
AU  - Antić, Darko
AU  - Karan-Đurašević, Teodora
AU  - Milić, N.
AU  - Todorovic-Balint, M.
AU  - Bila, J.
AU  - Anđelić, Boško
AU  - Đurašinović, Vladislava
AU  - Sretenović, A.
AU  - Smiljanić, M.
AU  - Jelicić, J.
AU  - Denčić-Fekete, Marija
AU  - Perunicić-Jovanović, M.
AU  - Kraguljac-Kurtović, N.
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1070
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia
EP  - 711
SP  - 710
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1070
ER  - 

@conference{
author = "Vuković, V. and Antić, Darko and Karan-Đurašević, Teodora and Milić, N. and Todorovic-Balint, M. and Bila, J. and Anđelić, Boško and Đurašinović, Vladislava and Sretenović, A. and Smiljanić, M. and Jelicić, J. and Denčić-Fekete, Marija and Perunicić-Jovanović, M. and Kraguljac-Kurtović, N. and Pavlović, Sonja and Mihaljević, B.",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia",
pages = "711-710",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1070"
}

Vuković, V., Antić, D., Karan-Đurašević, T., Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, B., Đurašinović, V., Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, M., Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, S.,& Mihaljević, B.. (2017). Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 710-711.
https://hdl.handle.net/21.15107/rcub_imagine_1070

Vuković V, Antić D, Karan-Đurašević T, Milić N, Todorovic-Balint M, Bila J, Anđelić B, Đurašinović V, Sretenović A, Smiljanić M, Jelicić J, Denčić-Fekete M, Perunicić-Jovanović M, Kraguljac-Kurtović N, Pavlović S, Mihaljević B. Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia. in Haematologica-The Hematology Journal. 2017;102:710-711.
https://hdl.handle.net/21.15107/rcub_imagine_1070 .

Vuković, V., Antić, Darko, Karan-Đurašević, Teodora, Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, Boško, Đurašinović, Vladislava, Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, Marija, Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, Sonja, Mihaljević, B., "Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia" in Haematologica-The Hematology Journal, 102 (2017):710-711,
https://hdl.handle.net/21.15107/rcub_imagine_1070 .

TY  - CONF
AU  - Virijević, M.
AU  - Djunić, I.
AU  - Novković, A.
AU  - Tošić, Nataša
AU  - Vidović, A.
AU  - Čolović, Nataša
AU  - Đurašinović, Vladislava
AU  - Suvajdžić-Vuković, Nada
AU  - Tomin, D.
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/602
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd
EP  - 509
SP  - 508
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_602
ER  - 

@conference{
author = "Virijević, M. and Djunić, I. and Novković, A. and Tošić, Nataša and Vidović, A. and Čolović, Nataša and Đurašinović, Vladislava and Suvajdžić-Vuković, Nada and Tomin, D.",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd",
pages = "509-508",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_602"
}

Virijević, M., Djunić, I., Novković, A., Tošić, N., Vidović, A., Čolović, N., Đurašinović, V., Suvajdžić-Vuković, N.,& Tomin, D.. (2012). Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 508-509.
https://hdl.handle.net/21.15107/rcub_imagine_602

Virijević M, Djunić I, Novković A, Tošić N, Vidović A, Čolović N, Đurašinović V, Suvajdžić-Vuković N, Tomin D. Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd. in Haematologica-The Hematology Journal. 2012;97:508-509.
https://hdl.handle.net/21.15107/rcub_imagine_602 .

Virijević, M., Djunić, I., Novković, A., Tošić, Nataša, Vidović, A., Čolović, Nataša, Đurašinović, Vladislava, Suvajdžić-Vuković, Nada, Tomin, D., "Prognostic impact of leukocytosis in patients with acute myeloid leukemia and mutated npm1 and flt3-itd" in Haematologica-The Hematology Journal, 97 (2012):508-509,
https://hdl.handle.net/21.15107/rcub_imagine_602 .